Latest
20
Oct
Royalty Deferral Structures in Pharmaceutical and Biotechnology Financing
Introduction
Royalty deferral structures represent sophisticated financing and licensing arrangements that fundamentally alter the timing and conditionality of royalty payments
21 min read
19
Oct
The Weekly Term Sheet (42)
Biotech and Pharmaceutical Deals: October 13-19, 2025
The week of October 13-19, 2025 marked one of the most active periods
16 min read
18
Oct
The great divide: Why royalty financing conquered North America but struggles everywhere else
Royalty financing in biotech and healthcare has exploded into a $5-6 billion annual market in North America, with transactions growing
25 min read
17
Oct
Fund of the Week: Blackstone Life Sciences
Background and Evolution
Blackstone Life Sciences (BXLS) is the life-sciences investment arm of Blackstone, the world's largest alternative
28 min read
16
Oct
Company of the week Soufflé Therapeutics
A delicate French dessert must rise perfectly under precise conditions. In biotechnology, Soufflé Therapeutics — a newly unveiled venture named after
20 min read
15
Oct
Variable Capital Companies (VCCs) in Singapore's Healthcare and Life Sciences Investments
Introduction
The Variable Capital Company (VCC) represents a transformative development in Singapore's fund management landscape, particularly for healthcare
21 min read
14
Oct
Special Purpose Vehicles in Pharma & Biotech – An In-Depth Explainer
Introduction
Special Purpose Vehicles (SPVs) play a pivotal role in the pharmaceutical and biotechnology sectors, facilitating innovative financing and structuring
26 min read
13
Oct
Understanding Bankruptcy Remoteness in Biotech Royalty Financing Deals
Bankruptcy remoteness is a crucial concept in structuring financial deals — especially royalty financing transactions in the biotechnology and pharmaceutical industry.
36 min read
12
Oct
The Weekly Term Sheet (41)
The week saw concentrated M&A activity focused on MASH and neurological assets totalling over $10 billion in deal
14 min read
11
Oct
Milestones and Mirages: Biotech's Big-Deal Delusions
The Allure of the "Up To" Deal
Every so often, a biotech startup announces a blockbuster partnership with
12 min read